montelukast and Hepatorenal-Syndrome

Hepatorenal syndrome (HRS) is a peculiar form of progressive renal failure complicating the course of cirrhosis and ascites. The renal impairment of HRS is merely functional and potentially reversible. Notwithstanding, in spite of several encouraging attempts, a satisfactory medical treatment for HRS is still expected. Several pathophysiological mechanisms are active in HRS. Arachidonate metabolism derangements are among these, and prostaglandins and thromboxane antagonists have been tried with variable outcomes. Also leukotrienes (LT) appear to be involved in HRS. Three drugs (zileuton, montelukast and zafirlukast) interfering with LT synthesis and receptor binding are currently available, but they have not yet been tried in HRS. Accordingly, the author would like to suggest physicians engaged in care of these critical patients to consider a trial with these drugs-as well as with any future innovative agent active on the arachidonate-derived metabolic pathways.

Topics: Acetates; Arachidonic Acid; Cyclopropanes; Hepatorenal Syndrome; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; Liver; Phenylcarbamates; Protein Structure, Tertiary; Quinolines; Sulfides; Sulfonamides; Thromboxanes; Tosyl Compounds